Author Question: A patient is administered Augmentin (amoxicillin and clavulanate potassium) to treat otitis media. ... (Read 111 times)

Garrulous · **on:** Jul 23, 2018

A patient is administered Augmentin (amoxicillin and clavulanate potassium) to treat otitis media. How does a beta-lactamase inhibitor agent achieve a therapeutic effect?

A) It extends the spectrum of antibacterial activity of penicillin.
B) It extends the spectrum of the beta-lactamase inhibitor.
C) It decreases the side effects of high-dose penicillin.
D) It increases the absorption of the penicillin.

Question 2

Duloxetine (Cymbalta) is being considered in the treatment of a patient's depression. Which of the following laboratory values would prevent the patient from being treated with this medication?

A) Decreased hemoglobin level
B) Decreased potassium level
C) Increased ALT
D) Increased erythrocyte sedimentation rate

ally · **Reply #1 on:** Jul 23, 2018

Answer to Question 1

A
Feedback:
When combined with a penicillin, the beta-lactamase inhibitor protects the penicillin from destruction by the enzymes and extends the penicillin's spectrum of antimicrobial activity. Augmentin does not extend the spectrum of beta-lactamase inhibitor. Augmentin does not decrease the side effects of high-dose penicillin. Augmentin does not increase the absorption of penicillin.

Answer to Question 2

C
Feedback:
Duloxetine (Cymbalta) is highly protein bound, extensively metabolized by CYP2D6 and CYP1A2 enzymes in the liver, and excreted by the kidneys. It is not recommended for use in patients with severe renal or any degree of liver impairment. Low hemoglobin, elevated potassium, and increased ESR do not necessarily preclude the use of Cymbalta.